The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Using MRD status as a metric of CAR-T efficacy in patients with multiple myeloma
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, shares insights into the merits of using measurable residual disease (MRD) status to assess the efficacy of CAR-T therapy in patients with multiple myeloma. Dr Lin highlights that for patients with bone marrow MRD negativity, positron emission tomography (PET) MRD status can be an additional prognostic measurement that can help clinicians closely monitor the efficacy of CAR-T. Moreover, MRD positivity in either the bone marrow or PET analysis is a strong indicator that patients will not achieve complete remission (CR) and require closer monitoring. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen: Consultancy, Research Funding; Gamida Cell: Consultancy; Celgene: Consultancy, Research Funding; Takeda: Research Funding; Merck: Research Funding; Vineti: Consultancy; Bluebird Bio: Consultancy, Research Funding; Sorrento: Consultancy; Legend: Consultancy; Kite, a Gilead Company: Consultancy, Research Funding; Juno: Consultancy; Novartis: Consultancy.
